Emerging therapeutic drugs for AML-Reference-Cited by-同舟云学术

Emerging therapeutic drugs for AML

Published:2016-01-07 Issue:1 Volume:127 Page:71-78
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Stein Eytan M.¹,Tallman Martin S.¹

Affiliation:

1. Leukemia Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY

Abstract

Abstract Multiple new drugs are being developed to treat acute myeloid leukemia (AML), including novel formulations of traditional chemotherapy-antibody drug conjugates and agents that target specific mutant enzymes. Next-generation sequencing has allowed us to discover the genetic mutations that lead to the development and clinical progression of AML. Studies of clonal hierarchy suggest which mutations occur early and dominate. This has led to targeted therapy against mutant driver proteins as well as the development of drugs such as CPX-351 and SGN-CD33A whose mechanisms of action and efficacy may not be dependent on mutational complexity. In this brief review, we discuss drugs that may emerge as important for the treatment of AML in the next 10 years.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/127/1/71/1391963/71.pdf

Reference64 articles.

1. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia.;Shlush;Nature,2014

2. Therapeutic advances in acute myeloid leukemia.;Burnett;J Clin Oncol,2011

3. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.;Bloomfield;Cancer Res,1998

4. Important milestones in acute leukemia in 2013.;Rowe;Best Pract Res Clin Haematol,2013

5. The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations.;Appelbaum;Br J Haematol,2006

Cited by 157 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rational design and optimization of novel 4-methyl quinazoline derivatives as PI3K/HDAC dual inhibitors with benzamide as zinc binding moiety for the treatment of acute myeloid leukemia;European Journal of Medicinal Chemistry;2024-01

2. A Metabolome and Microbiome Analysis of Acute Myeloid Leukemia: Insights into the Carnosine–Histidine Metabolic Pathway;Toxics;2023-12-22

3. Pinostrobin modulates FOXO3 expression, nuclear localization, and exerts antileukemic effects in AML cells and zebrafish xenografts;Chemico-Biological Interactions;2023-11

4. Big data and single‐cell sequencing in acute myeloid leukemia research;MedComm – Oncology;2023-08-28

5. Design, synthesis and pharmacological characterization of aminopyrimidine derivatives as BTK/FLT3 dual-target inhibitors against acute myeloid leukemia;Bioorganic Chemistry;2023-05